

Revision date 17-Jan-2025

Version 3.01

Page 1/13

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name	Pfizer-BioNTech COVID-19 Vaccine
Product Code(s) Form	PF00092 nanoform
Synonyms	Comirnaty; PF-07302048 containing PF-07305885 (BNT162b2); CorVAC Containing PF-07305885 (BNT162b2) ; CoVVAC Containing PF-07305885 (BNT162b2); COVID Vaccine Containing PF-07305885 (BNT162b2); COVID-19 Vaccine Containing PF-07305885 (BNT162b2)
Trade Name:	Not applicable
Compound Number	PF-07302048
Item Code	H000022941: H000023057,H000024547: H000024742, H000027229, H000027228
Chemical Family:	Lipid Nanoparticles containing PF-07305885 (BNT162b2) and Lipids

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** 

Pharmaceutical product

pfizer-MSDS@pfizer.com

#### 1.3. Details of the supplier of the safety data sheet

Pfizer Inc 66 Hudson Boulevard East New York, New York 10001 1-800-879-3477 Pfizer Ireland Pharmaceuticals OSG Building Ringaskiddy, Co. Cork. Ireland +353 21 4378701

#### E-mail address

1.4. Emergency telephone number

**Emergency Telephone** 

Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

### Section 2: HAZARDS IDENTIFICATION

#### 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous

<u>2.2. Label elements</u> Signal word	Not classified
Hazard statements	Not classified in accordance with international standards for workplace safety.
<u>2.3. Other hazards</u> Other hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Note:	This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

#### 3.1 Substances Substances

Not applicable

#### 3.2 Mixtures

Hazardous

Hazaluous			[	1	· · · · · ·		
Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
POTASSIUM CHLORIDE (CAS #: 7447-40-7)	< 1		231-211-8	Acute Tox 5 (H303)	Not Listed	No data available	No data available
NonHazardous							
Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
Sucrose (CAS #: 57-50-1)	< 10	-	200-334-9	Not classified as hazardous	Not Listed	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	< 10	-	231-598-3	Not classified as hazardous	Not Listed	No data available	No data available
ALC-0315 (CAS #: 2036272-55-4)	< 2	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Potassium phosphate (CAS #: 7778-77-0)	< 1	-	231-913-4	Not classified as hazardous	Not Listed	No data available	No data available
PF-07305885 (CAS #: -)	<1	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
PF-07302048 (CAS #: -)	< 1	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Disodium phosphate dihydrate (CAS #: 10028-24-7)	< 1		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Cholesterol (CAS #: 57-88-5)	< 1	-	200-353-2	Not classified as hazardous	Not Listed	No data available	No data available
ALC-0159 (CAS #: 1849616-42-7)	< 1	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
1,2-Distearoyl-sn-glyc	< 1	-	212-440-2	Not classified	Not Listed	No data	No data

ero-3-phosphocholine		as hazardous	available	available
(CAS #: 816-94-4)				

#### Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Sucrose 57-50-1	29700	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Potassium phosphate 7778-77-0	3200	No data available	0.83	No data available	No data available
POTASSIUM CHLORIDE 7447-40-7	3020	No data available	No data available	No data available	No data available
Cholesterol 57-88-5	>2000	>2000	No data available	No data available	No data available

#### Additional information

#### - Not Assigned

\* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

### Section 4: FIRST AID MEASURES

#### 4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.			
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.			
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.			
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.			
4.2. Most important symptoms and effects, both acute and delayed				
Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.			

4.3. Indication of any immediate medical attention and special treatment needed

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 17-Jan-2025

Note to physicians	None.			
Section 5: FIRE-FIGHTING MEASURES 5.1. Extinguishing media				
Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.			
5.2. Special hazards arising from th	e substance or mixture			
Specific hazards arising from the chemical	Fine particles (such as mists) may fuel fires/explosions.			
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.			
5.3. Advice for firefighters				
Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.			
Section 6: ACCIDENTAL REL	EASE MEASURES			
6.1. Personal precautions, protectiv	ve equipment and emergency procedures			
Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see			
For emergency responders	Section 8). Minimize exposure. Use personal protection recommended in Section 8.			
6.2. Environmental precautions				
Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.			
6.3. Methods and material for conta	inment and cleaning up			
Methods for containment Methods for cleaning up	Prevent further leakage or spillage if safe to do so. Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.			
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.			
6.4. Reference to other sections				
Reference to other sections	See section 8 for more information. See section 13 for more information.			
Section 7: HANDLING AND S	TORAGE			

#### 7.1. Precautions for safe handling

#### Advice on safe handling

Restrict access to work area. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Additional controls (based on risk assessment) should be implemented where open handling is required. Use enclosed manufacturing processing strategies. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

#### 7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions	Store as directed by product packaging.		
7.3. Specific end use(s)			
Specific use(s)	Vaccine.		
Section 8: EXPOSURE CONT	ROLS/PERSONAL PROTECTION		
8.1. Control parameters			
<b>Exposure Limits</b> Refer to available public information for	or specific member state Occupational Exposure Limits.		
Sucrose ACGIH TLV Bulgaria Estonia France Ireland Latvia Spain OSHA PEL	10 mg/m <sup>3</sup> 10.0 mg/m <sup>3</sup> 10 mg/m <sup>3</sup> 10 mg/m <sup>3</sup> STEL: 20 mg/m <sup>3</sup> 5 mg/m <sup>3</sup> 10 mg/m <sup>3</sup> 15 mg/m <sup>3</sup> 5 mg/m <sup>3</sup> 5 mg/m <sup>3</sup> 5 mg/m <sup>3</sup> 5 mg/m <sup>3</sup>		
United Kingdom	(vacated) TWA: 15 mg/m <sup>3</sup> total dust (vacated) TWA: 5 mg/m <sup>3</sup> respirable fraction TWA: 10 mg/m <sup>3</sup> STEL: 20 mg/m <sup>3</sup>		
SODIUM CHLORIDE Latvia Russia Potassium phosphate Russia POTASSIUM CHLORIDE Bulgaria Latvia Russia	5 mg/m <sup>3</sup> MAC: 5 mg/m <sup>3</sup> 5.0 mg/m <sup>3</sup> 5 mg/m <sup>3</sup> MAC: 5 mg/m <sup>3</sup> MAC: 5 mg/m <sup>3</sup>		
Pfizer Occupational Exposure Band (OEB) Statement:	The Vaccines Occupational Exposure Band (V-OEB) is a classification that has been assigned to biotechnology-based vaccines and antigen components. Risk assessments should be performed to assess potential exposures and determine appropriate controls. The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.		
SODIUM CHLORIDE Pfizer Occupational Exposure Band (OEB): ALC-0315	OEB 1 (control exposure to the range of 1000ug/m <sup>3</sup> to 3000ug/m <sup>3</sup> )		
Pfizer Occupational Exposure Band (OEB): POTASSIUM CHLORIDE	OEB 3 - Contact Hazards Unknown (control exposure to the range of 10ug/m <sup>3</sup> to < 100ug/m <sup>3</sup> )		
Pfizer Occupational Exposure Band (OEB): <b>PF-07305885</b>	OEB 1 (control exposure to the range of 1000ug/m <sup>3</sup> to 3000ug/m <sup>3</sup> )		

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 17-Jan-2025

V-OEB
V-OEB
OEB 3 - Contact Hazards Unknown (control exposure to the range of 10ug/m <sup>3</sup> to < 100ug/m <sup>3</sup> )
Release prevention and exposure protection measures should be established for any activities involving this material, as determined by a risk assessment conducted using appropriate Occupational Hygiene Risk Assessment tools. The containment level required for the activity should be based on the conclusions of the risk assessment. Where warranted, engineering controls, such as biosafety cabinets, should be applied as the primary means to control exposures.
No information available.
Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Wear impervious gloves, (e.g. Nitrile, etc.) to prevent skin contact. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Wear impervious disposable protective clothing when handling this compound. Full body protection is recommended (scale dependent). (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
If operating and handling conditions result in airborne exposure, wear an appropriate respirator with a protection factor sufficient to control exposures (e.g. particulate cartridge with a full face respirator, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

### Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties Physical state Color Odor Odor threshold Molecular formula Molecular weight	Liquid milky white No information available. No information available Mixture Mixture
<u>Property</u> pH Melting point / freezing point Boiling point / boiling range	<u>Values</u> 7.4 No data available

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 17-Jan-2025

Page 7/13 Version 3.01

Flash point **Evaporation rate** Flammability (solid, gas) Flammability Limit in Air Upper flammability limit:

Lower flammability limit:

Vapor pressure Vapor density **Relative density** Water solubility Solubility(ies) Partition coefficient Autoignition temperature **Decomposition temperature** Kinematic viscositv **Dvnamic viscositv Particle characteristics Particle Size Particle Size Distribution Explosive properties** 

Cholesterol Measured Log P >6.5

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes No information available

9.2.2. Other safety characteristics No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity No data available. Reactivity 10.2. Chemical stability Stability Stable under normal conditions. **Explosion data** Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available. 10.3. Possibility of hazardous reactions Possibility of hazardous reactions No information available. 10.4. Conditions to avoid Conditions to avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge. 10.5. Incompatible materials Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products Hazardous decomposition products No data available.

No data available No data available

No information available

No data available No data available

No information available No information available No information available

### Section 11: TOXICOLOGICAL INFORMATION

#### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	Toxicological properties have not been thoroughly investigated. The following information is available for the individual ingredients.
Short term	In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted.
Known Clinical Effects:	Based on clinical trials in humans, possible adverse effects following intravenous exposure to this compound may include: injection site pain, muscle pain, headache, fever, chills, tiredness, joint pain, abnormal redness of skin (erythema), and sleep disturbances. Serious allergic reactions, including anaphylaxis, have been reported.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

#### Acute Toxicity: (Species, Route, End Point, Dose) Sucrose

Rat Oral LD 50 29,700 mg/kg

#### SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup> Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg Cholesterol Rat Oral LD50 > 2000 mg/kg Rat Dermal LD50 > 2000 mg/kg POTASSIUM CHLORIDE Rat Oral LD50 3020 mg/kg Potassium phosphate Rat Oral LD50 3200 mg/kg Rabbit Dermal LC50 > 4640 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Sucrose	= 29700 mg/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat)1 h
Potassium phosphate	= 3200 mg/kg (Rat)	-	> 0.83 mg/L (Rat)4 h
POTASSIUM CHLORIDE	= 2600 mg/kg (Rat)	-	-
Cholesterol	>2000 mg/kg (Rat)	> 2000 mg/kg (Rat)	-

#### Irritation / Sensitization: (Study Type, Species, Severity) SODIUM CHLORIDE

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 17-Jan-2025

Skin irritation Rabbit Mild Eye irritation Rabbit Mild Cholesterol Skin irritation Epidermal Non-irritating Eye irritation Rabbit Non-irritating Skin Sensitization - LLNA Mouse Negative POTASSIUM CHLORIDE Eye Irritation Rabbit Mild				
Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)         Cholesterol         24 Week(s)       Mouse       Oral, in feed       1       % LOAEL       Liver         PF-07305885         17 Day(s)       Rat       Intramuscular       * 30       µg RNA/Dose       NOAEL       None identified				
PF-07302048 4 Week(s) Rat Intramuscular * 10 Repeated Dose Toxicity Comments	μg LOAEL Skin, Blood fo : <b>PF-07302048:</b> ** Doses γ	rming organs, Blood, were administered on	Skeletal muscle, Lyr ce a week.	nphoid tissue, Spleen
Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))         PF-07305885         Fertility & Embryonic Development - Females Rat Intramuscular 30 μg RNA/Dose NOAEL No effects at maximum dose, Not teratogenic         Potassium phosphate         Reproductive & Fertility Rat No route specified 282 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus Reproductive & Fertility Mouse No route specified 320 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus				
Genetic Toxicity: (Study Type, Cell Type/Organism, Result)         Cholesterol         Bacterial Mutagenicity (Ames)       Salmonella, E. coli         Negative         Potassium phosphate         Bacterial Mutagenicity (Ames)       Salmonella         Negative				
Carcinogenicity Cholesterol IARC	See below Group 3 (Not Classifiable)			
Data for the Drug Product				
Reproduction & Development Toxic	ity: (Study Type, Species, F	Route, Dose, End Po	int, Effect(s))	
Fertility & Embryonic R Development - Females	at Intramuscular	N/A	Not specified	No effects at maximum dose
11.2. Information on other hazards         11.2.1. Endocrine disrupting properties         Endocrine disrupting properties         No information available.				
11.2.2. Other information Other adverse effects	No information available.			
Section 12: ECOLOGICAL INFORMATION				
Environmental Overview:	Environmental properties habe avoided.	ave not been investiga	ated. Releases to the	e environment should

#### 12.1. Toxicity

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result) POTASSIUM CHLORIDE

Gambusia affinis (Mosquitofish) LC50 96 hours 920 mg/L Lepomis macrochirus (Bluegill Sunfish) LC50 96 hours 2010 mg/L Daphnia Magna (Water Flea) EC50 48 hours 825 mg/L Scenedesmus subspicatus (Green Alga) EC50 72 hours 2500 mg/L

#### 12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

**Bioaccumulation** 

No information available.

<u>Cholesterol</u> Measured Log P >6.5

#### 12.4. Mobility in soil

Mobility in soil No information available.

#### 12.5. Results of PBT and vPvB assessment

#### PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply
Potassium phosphate	The substance is not PBT / vPvB PBT assessment does
	not apply
POTASSIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply
Cholesterol	The substance is not PBT / vPvB

#### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

#### 12.7. Other adverse effects

No information available.

### Section 13: DISPOSAL CONSIDERATIONS

#### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 17-Jan-2025

### Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable
Special precautions for user:	Not applicable

### Section 15: REGULATORY INFORMATION

#### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS	Not Listed Not Listed Present 231-791-2 Present
Sucrose CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS SODIUM CHLORIDE	Not Listed Not Listed Present 200-334-9 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS AI C-0315	Not Listed Not Listed Present 231-598-3 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS Potassium phosphate	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS POTASSIUM CHLORIDE	Not Listed Not Listed Present 231-913-4 Present
CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS	Not Listed Not Listed Present 231-211-8

Product Name Pfizer-BioNTech COVID-19 Vaccine Revision date 17-Jan-2025

AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) PF-07305885	Present Schedule 4
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS PF-07302048	Not Listed Not Listed Not Listed
CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS	Not Listed Not Listed Not Listed
Disodium phosphate dihydrate CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Not Listed Not Listed Not Listed Present Schedule 5
Cholesterol CERCLA/SARA Section 313 de minimus % California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Not Listed Not Listed Present 200-353-2 Present Schedule 4
ALC-0159 CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS 1,2-Distearoyl-sn-glycero-3-phosphocholine CERCLA/SARA Section 313 de minimus % California Proposition 65 EINECS	Not Listed Not Listed Not Listed Not Listed Not Listed 212-440-2

#### France

**Occupational Illnesses (R-463-3, France)** 

Chemical name	French RG number	Title
SODIUM CHLORIDE	RG 78	-
7647-14-5		
POTASSIUM CHLORIDE	RG 67	-
7447-40-7		

#### **European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

#### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

#### **Persistent Organic Pollutants**

Not applicable

#### Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

#### Plant protection products directive (91/414/EEC)

Chemical name		Plant protection products directive (91/414/EEC)	
	Sucrose - 57-50-1		Plant protection agent
	SODIUM CHLORIDE - 7647-14	-5	Plant protection agent

Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances **AICS** - Australian Inventory of Chemical Substances

#### 15.2. Chemical safety assessment

Chemical Safety Report No information available

### Section 16: OTHER INFORMATION

#### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.5; H303 - May be harmful if swallowed

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reason for revision	SDS review
Revision date	17-Jan-2025
Prepared By	Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.